financetom
Business
financetom
/
Business
/
Datadog sees annual revenue, profit below estimates as enterprise spending lags
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Datadog sees annual revenue, profit below estimates as enterprise spending lags
Feb 13, 2025 5:42 AM

(Reuters) - Datadog ( DDOG ) forecast 2025 revenue and profit below Wall Street expectations on Thursday, hurt by sluggish customer spending on its cloud security services as enterprises cut budgets owing to economic uncertainty.

Shares of the New York-based company fell 10% in premarket trading.

Tough competition and high interest rates have weakened demand for Datadog's ( DDOG ) data monitoring services as enterprise customers rethink their spending priorities.

The cloud monitoring platform faces competition from firms such as Dynatrace ( DT ), which is trying to unify its security and data management platforms using artificial intelligence, making it easier for customers to find technical issues and breaches within their software.

Datadog ( DDOG ) forecast revenue between $3.18 billion and $3.20 billion for its fiscal 2025, compared with analysts' average estimate of $3.24 billion, according to data compiled by LSEG.

It forecast annual adjusted earnings per share between $1.65 and $1.70, while analysts expect $2.05.

First-quarter revenue forecast of $737 million and $741 million was also largely below the analyst estimate of $740.3 million.

It expects quarterly adjusted EPS between 41 cents and 43 cents per share, below estimates of 46 cents.

Revenue for the fourth quarter came in at $737.7 million, beating market expectations of $714.5 million.

(Reporting by Zaheer Kachwala in Bengaluru; Editing by Leroy Leo and Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA advisers to review Eli Lilly Alzheimer's drug
US FDA advisers to review Eli Lilly Alzheimer's drug
Jun 10, 2024
By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's ( LLY ) experimental Alzheimer's drug donanemab. Donanemab, if approved, would compete with Eisai ( ESALF ) and Biogen's Leqembi. Both drugs are designed to remove...
Market Chatter: Norway Wealth Fund Opposes Tesla CEO Musk's $56 Billion Pay
Market Chatter: Norway Wealth Fund Opposes Tesla CEO Musk's $56 Billion Pay
Jun 10, 2024
07:04 AM EDT, 06/10/2024 (MT Newswires) -- Norway's $1.7 trillion sovereign wealth fund will vote against ratifying Tesla chief (TSLA) Elon Musk's $56 billion pay package, which a Delaware judge invalidated earlier this year, Reuters reported on Saturday. We remain concerned about the total size of the award, the structure given performance triggers, dilution, and lack of mitigation of key...
Cuba woos Russians, Chinese to revive ailing tourist sector
Cuba woos Russians, Chinese to revive ailing tourist sector
Jun 10, 2024
HAVANA (Reuters) - Russian tourist Serguei Boyaryshnic wandered in awe among the pastel-colored buildings and cobblestone streets of Old Havana on a weekday morning, his family in tow. We had heard a lot about Cuba. Our countries have been friends for years, said the 36-year-old Moscow resident, who had joined a small tour group. We love everything about it. Cuba...
AstraZeneca's Tagrisso Secures Priority Review in the US
AstraZeneca's Tagrisso Secures Priority Review in the US
Jun 10, 2024
07:09 AM EDT, 06/10/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its supplemental new drug application for Tagrisso has been accepted and granted priority review in the US for the treatment of adult patients with unresectable, stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy. The Food and Drug Administration action date for a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved